ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DNAnexus to Showcase Platform Scalability, Versatility, and Security at ASHG 2022 Annual Meeting

Leading human geneticists and bioinformaticians to share latest data-driven insights that can help advance precision medicine and improve patient care

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the speaker lineup for its customer presentations at the American Society of Human Genetics (ASHG) 2022 Annual Meeting, which is being held in Los Angeles this week. The company will also be showcasing its GxP-compliant platform and new Nextflow pipeline language support capabilities in booth #2103.

“The rapidly evolving genomic and multi-omic ecosystem has created an enormous need for a scalable and compliant analysis platform that drives critical insights from massive datasets,” said Stephen Nuckols, Chief Commercial Officer at DNAnexus. “We look forward to hearing from several visionary scientists about how they are using our platform to push the boundaries of human genetics and tackle the most exciting opportunities in precision medicine.”

FEATURED PRESENTATIONS

Using Genomic Data to Drive Precision Medicine Insights

Wednesday, Oct. 26, 2022; 12:30 pm – 1:30 pm (lunch provided)

Room 306, Convention Center South Building

  • Partnering with DNAnexus to Unlock Myriad’s Precise™ Treatment Registry

    Kevin Haas, PhD, Chief Technology Officer, Myriad Genetics
  • The City of Hope POSEIDON Platform: Driving Cancer Insights with Real-World Data

    Samir Courdy, Senior Vice President and Chief Informatics Officer, City of Hope

Detection of Clonal Hematopoiesis in the UK Biobank and Association with Health Outcomes

Wednesday, Oct. 26, 2022; 3:45 pm – 4:15 pm

Theater 2, Convention Center Exhibit Hall

  • Kelly Bolton, MD, PhD, Assistant Professor, Washington University School of Medicine
  • Ben Busby, PhD, Senior Director of Solution Science, DNAnexus

To register for these presentations, please visit: https://hello.dnanexus.com/american-society-of-human-genetics-2022-conference.

Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. The platform provides a comprehensive cloud environment that was designed to meet the most rigorous standards for quality, security, privacy, and safety.

About DNAnexus

DNAnexus is a leading provider of secure, scalable, and intuitive biomedical data analysis software and bioinformatics applications for the life sciences and healthcare communities. The company actively manages and supports more than 65 petabytes of complex genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborations with large-scale biobanks, as well as leading pharmaceutical, clinical diagnostic, academic research, and government organizations. Scientists across 48 countries are now using the highly collaborative, cloud-based, end-to-end platform to gain data-driven insights that can advance scientific discovery, accelerate precision medicine, and improve patient care. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.